Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Carfilzomib (Kyprolis): A Novel Proteasome Inhibitor for Relapsed And/or Refractory Multiple Myeloma.

Literature DB >> 27162470

Carfilzomib (Kyprolis): A Novel Proteasome Inhibitor for Relapsed And/or Refractory Multiple Myeloma.

Galina Perel, Joshua Bliss, Christan M Thomas.

Abstract

Entities: Chemical Disease

Year: 2016 PMID： 27162470 PMCID： PMC4849338

Source DB: PubMed Journal: P T ISSN： 1052-1372

× No keyword cloud information.

6 in total

1. Quality of Life assessment through the EORTC questionnaires of colorectal cancer patients in advanced disease stages.

Authors: Juan Ignacio Arraras Urdaniz; Ruth Vera García; Maite Martínez Aguillo; Ana Manterola Burgaleta; Fernando Arias de la Vega; Esteban Salgado Pascual
Journal: Clin Transl Oncol Date: 2006-09 Impact factor: 3.405

Review 2. Structure and functions of the 20S and 26S proteasomes.

Authors: O Coux; K Tanaka; A L Goldberg
Journal: Annu Rev Biochem Date: 1996 Impact factor: 23.643

Review 3. Molecular pathogenesis of multiple myeloma and its premalignant precursor.

Authors: W Michael Kuehl; P Leif Bergsagel
Journal: J Clin Invest Date: 2012-10-01 Impact factor: 14.808

4. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Authors: A Keith Stewart; S Vincent Rajkumar; Meletios A Dimopoulos; Tamás Masszi; Ivan Špička; Albert Oriol; Roman Hájek; Laura Rosiñol; David S Siegel; Georgi G Mihaylov; Vesselina Goranova-Marinova; Péter Rajnics; Aleksandr Suvorov; Ruben Niesvizky; Andrzej J Jakubowiak; Jesus F San-Miguel; Heinz Ludwig; Michael Wang; Vladimír Maisnar; Jiri Minarik; William I Bensinger; Maria-Victoria Mateos; Dina Ben-Yehuda; Vishal Kukreti; Naseem Zojwalla; Margaret E Tonda; Xinqun Yang; Biao Xing; Philippe Moreau; Antonio Palumbo
Journal: N Engl J Med Date: 2014-12-06 Impact factor: 91.245

5. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Authors: David S Siegel; Thomas Martin; Michael Wang; Ravi Vij; Andrzej J Jakubowiak; Sagar Lonial; Suzanne Trudel; Vishal Kukreti; Nizar Bahlis; Melissa Alsina; Asher Chanan-Khan; Francis Buadi; Frederic J Reu; George Somlo; Jeffrey Zonder; Kevin Song; A Keith Stewart; Edward Stadtmauer; Lori Kunkel; Sandra Wear; Alvin F Wong; Robert Z Orlowski; Sundar Jagannath
Journal: Blood Date: 2012-07-25 Impact factor: 22.113

Review 6. Carfilzomib.

Authors: K Martin Kortuem; A Keith Stewart
Journal: Blood Date: 2013-02-07 Impact factor: 22.113

6 in total

1. The role of the ubiquitin-proteasome pathway in skin cancer development: 26S proteasome-activated NF-κB signal transduction.

Authors: Ouadie Mohamed El Yaagoubi; Larbi Oularbi; Abdelhakim Bouyahya; Hamid Samaki; Said El Antri; Souad Aboudkhil
Journal: Cancer Biol Ther Date: 2021-09-29 Impact factor: 4.875

Carfilzomib (Kyprolis): A Novel Proteasome Inhibitor for Relapsed And/or Refractory Multiple Myeloma.

1. Quality of Life assessment through the EORTC questionnaires of colorectal cancer patients in advanced disease stages.

Review 2. Structure and functions of the 20S and 26S proteasomes.

Review 3. Molecular pathogenesis of multiple myeloma and its premalignant precursor.

4. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.

5. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Review 6. Carfilzomib.

1. The role of the ubiquitin-proteasome pathway in skin cancer development: 26S proteasome-activated NF-κB signal transduction.

Review 2. Small Molecule NF-κB Pathway Inhibitors in Clinic.

Review 3. Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma.

Review 4. Novel agents in the treatment of multiple myeloma: a review about the future.

5. Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis.

6. Burkholderia multivorans: A rare yet emerging cause of bacterial meningitis.